The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Share News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wife of DS Smith CEO sells 5.6m-pound stake

Wed, 24th Jul 2013 15:53

The wife of DS Smith frontman Miles Roberts sold a substantial sum of shares in the packaging and office supplies firm on the same day it was revealed the Chief Executive Officer (CEO) received a big pay increase last year.The move came on Tuesday, the same day DS Smith released its annual report in which it said the CEO had earned a total of £1.6m for the fiscal year ended April 30th, up from £1.3m the year before. This included an annual salary of £0.61m and bonuses totalling £0.76m, in addition to pension payments and other benefits.Gillian Roberts exercised nil-cost options over nearly 2.6m shares and subsequently sold around 2.22m of them at a price of 250.53p each, making a total of nearly £5.6m.The couple's total holding following the transaction was left at just under 0.6m shares, equal to a 0.064% stake.The stock has risen by over 20% so far in 2013.Top Director BuysBanco Santander SA (BNC) Director name: Mr Emilio BotinAmount purchased: 13,430 @ 420.84p Value: £56,519Banco Santander SA (BNC) Director name: Mr Emilio BotinAmount purchased: 11,084 @ 418.86p Value: £46,426Croda International (CRDA) Director name: Mr Martin FlowerAmount purchased: 2,000 @ 2,424.99p Value: £48,500VP (VP.) Director name: Mr Neil A StothardAmount purchased: 8,500 @ 407.00p Value: £34,595VP (VP.) Director name: Ms Allison BainbridgeAmount purchased: 5,500 @ 408.00p Value: £22,440Banco Santander SA (BNC) Director name: Mr Emilio BotinAmount purchased: 4,000 @ 418.77p Value: £16,751Scientific Digital Imaging (SDI) Director name: Mr Kenneth FordAmount purchased: 100,000 @ 16.50p Value: £16,500Faroe Petroleum (FPM) Director name: Mr Roger WittsAmount purchased: 10,000 @ 111.50p Value: £11,150Top Director SellsSmith (DS) (SMDS) Director name: Mr Miles RobertsAmount sold: 2,218,519 @ 250.53p Value: £5,558,056e-Therapeutics (ETX) Director name: Mr Malcolm YoungAmount sold: 1,230,177 @ 35.50p Value: £436,713SThree (STHR) Director name: Mr Steve QuinnAmount sold: 101,633 @ 335.09p Value: £340,562e-Therapeutics (ETX) Director name: Mr Malcolm YoungAmount sold: 125,059 @ 27.00p Value: £33,766e-Therapeutics (ETX) Director name: Mr Malcolm YoungAmount sold: 50,000 @ 27.00p Value: £13,500BC
More News
20 Mar 2018 16:14

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 21 March KingfisherFull Year ResultsAlpha FXFull Year In SportFull 22

Read more
9 Jan 2017 08:49

E-Therapeutics Hires Amgen Director As New Chief Executive

Read more
6 Oct 2016 11:23

DIRECTOR DEALINGS: e-Therapeutics Non-Executive Acquires Shares

Read more
14 Sep 2016 11:23

e-Therapeutics Development Director Steve Self To Step Down

Read more
13 Jul 2016 09:13

E-Therapeutics Chairman Takes On Executive Duties As CEO Steps Down

Read more
1 Jun 2016 08:03

e-Therapeutics Offer For Searchbolt Now Wholly Unconditional

Read more
25 May 2016 08:18

e-Therapeutics Focused On Validation Of Drug Discovery Platform

Read more
18 May 2016 15:05

AGM, EGM Calendar - Week Ahead

Read more
12 May 2016 11:13

DIRECTOR DEALINGS: E-Therapeutics Non-Executive Acquires Shares

Read more
11 May 2016 09:06

e-Therapeutics To Buy Searchbolt For GBP2.3 Million (ALLISS)

Read more
22 Mar 2016 11:40

E-Therapeutics Loss Widens As Active Projects Increase

Read more
15 Mar 2016 16:15

Earnings, Trading Statements Calendar - Week Ahead

Read more
15 Feb 2016 10:43

WINNERS & LOSERS SUMMARY: Reckitt Benckiser Results Please Investors

Read more
15 Feb 2016 09:45

E-Therapeutics depression drug trials miss targets

(ShareCast News) - Drug trials results for e-Therapeutics' depression treatment were not as successful as had been hoped, sending shares in the company sharply lower. Phase IIb clinical trials of the company's ETS6103 product did not achieve the aim of matching the efficacy of existing tricyclic ant

Read more
15 Feb 2016 08:20

E-Therapeutics Shares Drop As ETS6103 Trials Miss Primary Endpoint

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.